The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
To determine the overall response rate of cetuximab alone in subjects with ovarian or primary peritoneal carcinoma who have persistent or recurrent disease following 1-2 previous regimens of chemotherapy. Potential relationship between response, dose, and the occurence of rash in the treatment of subjects who have stable disease after the initial 6 weeks of treatment, time to progression, and 1 yr survival.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
25
400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
ImClone Investigational Site
Birmingham, Alabama, United States
ImClone Investigational Site
Orlando, Florida, United States
ImClone Investigational Site
New York, New York, United States
ImClone Investigational Site
Philadelphia, Pennsylvania, United States
Overall response rate
Time frame: Every six weeks
Relationship between response, dose, and occurence of rash
Time frame: Every six weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
ImClone Investigational Site
Seattle, Washington, United States